TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07433335: Phase 1b Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis

Sponsor: SciRhom GmbH · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,847,440

Rescue Site Savings

+$2,533,680

Unlock Full NCT07433335 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07433335 Rescue Dossier →